Andrew White is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3811 Valley Centre Dr
San Diego, CA 921303318
Telephone
858-764-9010Provider last certified this registry record 14 Feb 2020.
Clinical trials
- Optimizing Video Communication Assessment for Teaching Error Disclosure Skills
Sponsor: University of Washington
- Evaluating Adapted Structured Clinical Management for People With a Diagnosis of Personality Disorder
Sponsor: Camden and Islington NHS Trust
- Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)
Sponsor: Cumberland Pharmaceuticals
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
50 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Healthcare Solutions, Inc.Program year202540 payments$42,837openpaymentsdata.cms.gov ↗
- GlaxoSmithKline, LLC.Program year202550 payments$36,994openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year202521 payments$17,396openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
98.5%Anti-IgE34.1%Omalizumab99%Xolair1%Part D + Part B<11 patientsInterleukin-5 Antagonist32.5%Mepolizumab100%Nucala1%Part D + Part B<11 patients+ 7 more classes in this area
Dermatology
0.6%Interleukin-4 Receptor alpha Antagonist0.5%Dupixent Pen74%Dupixent Syringe26%Part D<11 patientsCorticosteroid0.1%Methylprednisolone57%Triamcinolone Acetonide43%Part D<11 patientsMetabolism & gastrointestinal
0.3%Corticosteroid0.3%Prednisone100%Part D≥41 patientsH2 blocker0.1%Famotidine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2011–2011 per NIH RePORTER. The latest:
- MOLECULAR MECHANISM OF ACTIVATION OF A NOVEL INTRACELLULAR CAMP RECEPTOR
Stanford University
FY2011$559P41RR001209
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”